# CLCN7

## Overview
The CLCN7 gene encodes the chloride voltage-gated channel 7 (ClC-7), a transmembrane protein that functions as a chloride/proton exchanger. This protein is integral to maintaining ionic homeostasis within lysosomes and osteoclasts, playing a pivotal role in bone resorption and lysosomal function. ClC-7 is primarily localized in lysosomes and the ruffled border of osteoclasts, where it facilitates the acidification necessary for bone degradation and lysosomal enzyme activity (Stauber2012Cell; Kornak2001Loss). The protein forms a complex with Ostm1, which is essential for its stability and function, highlighting its importance in cellular physiology (Zhang2020Molecular). Mutations in CLCN7 are associated with osteopetrosis and other lysosomal storage disorders, underscoring its clinical significance (Zifarelli2022The; Cleiren2001AlbersSchonberg).

## Structure
The CLCN7 gene encodes the ClC-7 protein, a chloride channel involved in lysosomal function and bone resorption. ClC-7 is an 89-kDa protein composed of 805 amino acids in humans, featuring a large transmembrane domain and two COOH-terminal cystathionine β-synthase (CBS) domains (Di2020Pathobiologic; Jentsch2018CLC). The transmembrane region consists of 24 α-helices and 5 β-strands, forming an extensive structure that spans the cellular membrane (Zhang2020Molecular). 

The protein functions as a homodimer, with each monomer containing an ion permeation pathway characterized by a highly conserved glutamate residue acting as the external gate (Di2020Pathobiologic). The ClC-7/Ostm1 complex is stabilized by hydrophobic and polar interactions between their transmembrane domains, with Ostm1 acting as a lid above ClC-7 (Zhang2020Molecular). 

Post-translational modifications include glycosylation of the Ostm1 subunit, which is crucial for the stability of the complex in lysosomal environments (Zhang2020Molecular). The ClC-7 protein is primarily localized in lysosomes and the ruffled border of osteoclasts, essential for its physiological roles (Jentsch2018CLC).

## Function
The CLCN7 gene encodes the ClC-7 protein, a chloride/proton exchanger that plays a crucial role in maintaining ionic homeostasis within lysosomes and osteoclasts. ClC-7 is primarily localized to lysosomes and the ruffled border of osteoclasts, where it facilitates the acidification necessary for bone resorption and lysosomal function (Stauber2012Cell; Kornak2001Loss). In osteoclasts, ClC-7 is coinserted with the vesicular H+-ATPase into the ruffled border membrane, providing the chloride conductance required for efficient proton pumping, which is essential for the dissolution of bone mineral and degradation of the organic bone matrix (Stauber2012Cell; Kornak2001Loss).

In lysosomes, ClC-7 functions as a Cl-/H+ antiporter, contributing to the acidification process necessary for lysosomal enzyme activity and proper cellular trafficking (Weinert2014Transport; Zhang2020Molecular). The protein's activity is crucial for maintaining the acidic environment required for lysosomal function, and its dysfunction can lead to lysosomal storage disorders and neurodegeneration (Stauber2012Cell; Zifarelli2022The). ClC-7's role in these processes highlights its importance in bone resorption and lysosomal physiology, impacting overall cellular and organismal health.

## Clinical Significance
Mutations in the CLCN7 gene are associated with various forms of osteopetrosis, a group of genetic bone disorders characterized by increased bone density and fragility. Autosomal dominant osteopetrosis type II (ADO-II), also known as Albers-Schönberg disease, is linked to heterozygous mutations in CLCN7 and presents with relatively mild symptoms such as bone sclerosis and remodeling defects. These symptoms can range from asymptomatic to severe, with potential complications including non-traumatic fractures, nerve compression syndrome, and bone marrow failure (Rashid2013A; Zifarelli2022The; Cleiren2001AlbersSchonberg). 

In contrast, autosomal recessive osteopetrosis (ARO) is associated with homozygous or compound heterozygous mutations in CLCN7 and is more severe, often leading to early mortality if untreated. ARO can result in severe brain abnormalities, respiratory failure, and defective autophagy (Zifarelli2022The; Pang2015Novel). 

CLCN7 mutations have also been linked to extra-skeletal manifestations, including renal tubular acidosis, renal stones, epilepsy, and blindness, indicating a broader impact beyond bone pathology (Zifarelli2022The; Piret2016Autosomal). The gene's role in neurodegeneration and its potential involvement in Alzheimer's disease have also been noted (Zifarelli2022The).

## Interactions
CLCN7, encoding the chloride voltage-gated channel 7, interacts primarily with the Ostm1 protein. This interaction is crucial for the stability and function of ClC-7, as Ostm1 acts as a β-subunit, facilitating ClC-7's role in bone resorption and lysosomal function. The ClC-7/Ostm1 complex is essential for the proper trafficking of Ostm1 from the endoplasmic reticulum to lysosomes, and without ClC-7, Ostm1 fails to localize to lysosomes, remaining in the ER (Lange2006ClC7; Leisle2011ClC7).

The interaction between ClC-7 and Ostm1 involves transmembrane helices, with the transmembrane domain of Ostm1 being necessary and sufficient for ClC-7's lysosomal trafficking. The aminoterminus of Ostm1 is also required for ClC-7's ion transport activity (Leisle2011ClC7). This interaction is specific to ClC-7 and does not occur with related proteins such as ClC-3 or ClC-6 (Lange2006ClC7).

Mutations in CLCN7 can disrupt this interaction, leading to conditions like osteopetrosis and lysosomal storage diseases. These mutations may affect ion transport or the activation mechanism by Ostm1, highlighting the importance of their interaction for ClC-7's function (Leisle2011ClC7; Zhang2020Molecular).


## References


[1. (Lange2006ClC7) Philipp F. Lange, Lena Wartosch, Thomas J. Jentsch, and Jens C. Fuhrmann. Clc-7 requires ostm1 as a β-subunit to support bone resorption and lysosomal function. Nature, 440(7081):220–223, March 2006. URL: http://dx.doi.org/10.1038/nature04535, doi:10.1038/nature04535. This article has 291 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature04535)

[2. (Cleiren2001AlbersSchonberg) E. Cleiren. Albers-schonberg disease (autosomal dominant osteopetrosis, type ii) results from mutations in the clcn7 chloride channel gene. Human Molecular Genetics, 10(25):2861–2867, December 2001. URL: http://dx.doi.org/10.1093/hmg/10.25.2861, doi:10.1093/hmg/10.25.2861. This article has 303 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/10.25.2861)

[3. (Zhang2020Molecular) Sensen Zhang, Yang Liu, Bing Zhang, Jun Zhou, Tianyu Li, Zhiqiang Liu, Yang Li, and Maojun Yang. Molecular insights into the human clc-7/ostm1 transporter. Science Advances, August 2020. URL: http://dx.doi.org/10.1126/sciadv.abb4747, doi:10.1126/sciadv.abb4747. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciadv.abb4747)

[4. (Di2020Pathobiologic) Eleonora Di Zanni, Eleonora Palagano, Laura Lagostena, Dario Strina, Asma Rehman, Mario Abinun, Lien De Somer, Baldassarre Martire, Justin Brown, Ariana Kariminejad, Shanti Balasubramaniam, Gareth Baynam, Fiorella Gurrieri, Maria A Pisanti, Ilaria De Maggio, Miguel R Abboud, Robert Chiesa, Christine P Burren, Anna Villa, Cristina Sobacchi, and Alessandra Picollo. Pathobiologic mechanisms of neurodegeneration in osteopetrosis derived from structural and functional analysis of 14 clc-7 mutants. Journal of Bone and Mineral Research, 36(3):531–545, October 2020. URL: http://dx.doi.org/10.1002/jbmr.4200, doi:10.1002/jbmr.4200. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/jbmr.4200)

[5. (Rashid2013A) Ban Mousa Rashid, Nawshirwan Gafoor Rashid, Ansgar Schulz, Georgia Lahr, and Beston Faiek Nore. A novel missense mutation in the clcn7 gene linked to benign autosomal dominant osteopetrosis: a case series. Journal of Medical Case Reports, January 2013. URL: http://dx.doi.org/10.1186/1752-1947-7-7, doi:10.1186/1752-1947-7-7. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1752-1947-7-7)

[6. (Zifarelli2022The) Giovanni Zifarelli. The role of the lysosomal cl−/h+ antiporter clc-7 in osteopetrosis and neurodegeneration. Cells, 11(3):366, January 2022. URL: http://dx.doi.org/10.3390/cells11030366, doi:10.3390/cells11030366. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11030366)

[7. (Weinert2014Transport) Stefanie Weinert, Sabrina Jabs, Svea Hohensee, Wing Lee Chan, Uwe Kornak, and Thomas J Jentsch. Transport activity and presence of clc‐7/ostm1 complex account for different cellular functions. EMBO reports, 15(7):784–791, May 2014. URL: http://dx.doi.org/10.15252/embr.201438553, doi:10.15252/embr.201438553. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.15252/embr.201438553)

[8. (Jentsch2018CLC) Thomas J. Jentsch and Michael Pusch. Clc chloride channels and transporters: structure, function, physiology, and disease. Physiological Reviews, 98(3):1493–1590, July 2018. URL: http://dx.doi.org/10.1152/physrev.00047.2017, doi:10.1152/physrev.00047.2017. This article has 308 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1152/physrev.00047.2017)

[9. (Stauber2012Cell) Tobias Stauber, Stefanie Weinert, and Thomas J. Jentsch. Cell biology and physiology of clc chloride channels and transporters. July 2012. URL: http://dx.doi.org/10.1002/cphy.c110038, doi:10.1002/cphy.c110038. This article has 124 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cphy.c110038)

[10. (Kornak2001Loss) Uwe Kornak, Dagmar Kasper, Michael R Bösl, Edelgard Kaiser, Michaela Schweizer, Ansgar Schulz, Wilhelm Friedrich, Günter Delling, and Thomas J Jentsch. Loss of the clc-7 chloride channel leads to osteopetrosis in mice and man. Cell, 104(2):205–215, January 2001. URL: http://dx.doi.org/10.1016/s0092-8674(01)00206-9, doi:10.1016/s0092-8674(01)00206-9. This article has 812 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(01)00206-9)

[11. (Pang2015Novel) Q. Pang, Y. Chi, Z. Zhao, X. Xing, M. Li, O. Wang, Y. Jiang, R. Liao, Y. Sun, J. Dong, and W. Xia. Novel mutations of clcn7 cause autosomal dominant osteopetrosis type ii (ado-ii) and intermediate autosomal recessive osteopetrosis (iaro) in chinese patients. Osteoporosis International, 27(3):1047–1055, September 2015. URL: http://dx.doi.org/10.1007/s00198-015-3320-x, doi:10.1007/s00198-015-3320-x. This article has 22 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00198-015-3320-x)

[12. (Leisle2011ClC7) Lilia Leisle, Carmen F Ludwig, Florian A Wagner, Thomas J Jentsch, and Tobias Stauber. Clc-7 is a slowly voltage-gated 2cl−/1h+-exchanger and requires ostm1 for transport activity: slowly voltage-gated 2cl/h-exchange by clc-7/ostm1. The EMBO Journal, 30(11):2140–2152, April 2011. URL: http://dx.doi.org/10.1038/emboj.2011.137, doi:10.1038/emboj.2011.137. This article has 184 citations.](https://doi.org/10.1038/emboj.2011.137)

[13. (Piret2016Autosomal) Sian E. Piret, Caroline M. Gorvin, Anne Trinh, John Taylor, Stefano Lise, Jenny C. Taylor, Peter R. Ebeling, and Rajesh V. Thakker. Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a clcn7 mutation. American Journal of Medical Genetics Part A, 170(11):2988–2992, August 2016. URL: http://dx.doi.org/10.1002/ajmg.a.37755, doi:10.1002/ajmg.a.37755. This article has 10 citations.](https://doi.org/10.1002/ajmg.a.37755)